Alzheimer’s Biomarkers in Dental Practice: Is Innovation Outpacing Readiness?
Practices should be cautious about adopting complex biomarker tests such as APOE genotyping and blood-based Tau assays. Here's why.
To the editor,
Let me begin by saying my passion has been advancing Alzheimer’s prevention through the lens of oral health, a focus I have pursued for nearly a decade. During that time, I have worked across both the dental profession and the preventive neurology space to help bridge disciplines, translate emerging science, and promote earlier risk recognition.
As enthusiasm grows for precision medicine and Alzheimer’s prevention, some in my own dental field have proposed expanding biomarker testing—including APOE genotyping and blood-based phosphorylated Tau assays—into dental practices. While interdisciplinary innovation should be welcomed, the scientific and ethical complexities of these tests warrant far greater caution than is sometimes acknowledged...
Click Here to Read More
To the editor,
Let me begin by saying my passion has been advancing Alzheimer’s prevention through the lens of oral health, a focus I have pursued for nearly a decade. During that time, I have worked across both the dental profession and the preventive neurology space to help bridge disciplines, translate emerging science, and promote earlier risk recognition.
As enthusiasm grows for precision medicine and Alzheimer’s prevention, some in my own dental field have proposed expanding biomarker testing—including APOE genotyping and blood-based phosphorylated Tau assays—into dental practices. While interdisciplinary innovation should be welcomed, the scientific and ethical complexities of these tests warrant far greater caution than is sometimes acknowledged...
Click Here to Read More